H.C. Wainwright lowered the firm’s price target on Oncternal Therapeutics to $19 from $28 and keeps a Buy rating on the shares post the Q1 report. The analyst cites the company’s additional equity financings in the future for the target drop.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCT:
- Oncternal Therapeutics reports Q1 EPS ($2.83), consensus ($2.88)
- Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
- Oncternal Therapeutics reports inducement award under Nasdaq listing rule
- Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- ONCT Earnings this Week: How Will it Perform?